Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +62

What Investors Don’t Understand About Abbott Laboratories

AI-generated analysis

📉 Abbott trades at 17x forward earnings with shares down 28.8% year-to-date, yet the stock has posted four consecutive EPS beats.

💊 The company is a Dividend Aristocrat with a 54th consecutive year of dividend increases and a quarterly payout of $0.63 per share.

🩸 Medical Devices became the dominant engine, generating $5.54 billion in Q1 2026, up 13.2% from the prior period.

📱 The FreeStyle Libre CGM franchise cleared $2.08 billion in Q1 2026, growing 13.8% as the market expands toward 80 million users.

🧬 Abbott closed its $21 billion acquisition of Exact Sciences on March 23, 2026, launching a new Cancer Diagnostics unit.

🛡️ The Cologuard cancer test is expected to generate roughly $3 billion in incremental sales for 2026 with 95% sensitivity.

💰 Established Pharmaceuticals grew 13.2% while international sales rose 11.3% in the first quarter of 2026.

📉 Nutrition revenue fell 6.0% to $2.02 billion as management deliberately focused on products with positive volume responses to price reductions.

⚠️ Challenges include competition from DexCom, China volume-based procurement, and $0.20 per share of Exact Sciences dilution.

Bullish Signals
  • Abbott posted four consecutive EPS beats with adjusted Q1 2026 EPS at $1.15, exceeding market expectations.
  • The FreeStyle Libre CGM franchise generated $2.08 billion in Q1 2026, growing 13.8% as the global market expands significantly.
  • Medical Devices revenue surged to $5.54 billion in Q1 2026, up 13.2%, establishing it as the company's dominant growth engine.
  • The $21 billion Exact Sciences acquisition is expected to contribute approximately $3 billion in incremental sales for 2026.
  • Established Pharmaceuticals grew 13.2% and international sales rose 11.3%, demonstrating resilience across key segments.
  • Abbott maintains a 54th consecutive year of dividend increases, reinforcing its status as a Dividend Aristocrat with a $0.63 quarterly payout.
Risk Factors
  • Nutrition revenue declined 6.0% to $2.02 billion in Q1 2026 as the company pivots away from legacy baby formula and branded generics.
  • Shares are down 28.8% year-to-date and 32.1% over one year, trading well below the analyst consensus buy target of $116.54.
Full Analysis
Abbott Laboratories (NYSE: ABT) is trading at a forward P/E of 17x, significantly below its $137.49 52-week high and the $116.54 analyst consensus target, despite posting four consecutive EPS beats. The market continues to price the stock as a slow-and-steady dividend stalwart with a beta of 0.607, but management argues this framing undervalues the company's strategic transformation into a growth-oriented compounder. The company is pivoting toward high-growth medical devices, where the FreeStyle Libre continuous glucose monitor franchise generated $2.08 billion in Q1 2026, up 13.8%. CEO Robert Ford highlights a massive runway for the global CGM market, projecting growth from 12 million to 80 million users, while established pharmaceuticals and international sales also posted double-digit growth of 13.2% and 11.3% respectively. A major catalyst is the $21 billion acquisition of Exact Sciences, which closed on March 23, 2026, adding Cologuard cancer diagnostics to the portfolio. Management expects this unit to generate approximately $3 billion in incremental sales for 2026, driven by high sensitivity and convenience that addresses a screening gap among 50 million Americans.